How should pulmonary arterial hypertension be managed with a combination of sildenafil and bosentan?

Management of PAH with Sildenafil and Bosentan Combination

The combination of bosentan and sildenafil should generally be avoided in PAH management due to insufficient evidence of efficacy and significant pharmacokinetic interactions that reduce sildenafil plasma concentrations by approximately 50-70%. 1, 2, 3

Critical FDA Warning

The FDA label for sildenafil explicitly states: "The efficacy of sildenafil tablets in the treatment of pulmonary arterial hypertension (PAH) has not been adequately evaluated in patients taking bosentan." 1 This is a clear limitation of use that should guide clinical decision-making.

Evidence Against This Combination

Lack of Clinical Benefit

The COMPASS-2 trial 4, a prospective, double-blind, event-driven study of 334 PAH patients, demonstrated that adding bosentan to stable sildenafil therapy failed to show superiority over sildenafil monotherapy for the primary endpoint of time to first morbidity/mortality event (hazard ratio 0.83,97.31% CI 0.58-1.19; p=0.25). While there was a statistically significant increase in 6-minute walk distance (+21.8 m), this fell below the clinically meaningful threshold of 33 meters established by the 2019 CHEST guidelines 5.

A second randomized controlled trial 6 adding sildenafil to stable bosentan showed no benefit over placebo for 12-week change in 6MWD (least squares mean difference -2.4 m, 90% CI: -21.8 to 17.1 m; p=0.6).

Significant Drug Interaction

Bosentan reduces sildenafil plasma concentrations by 50% at the 62.5 mg dose and by 69% at the 125 mg dose through CYP3A4 induction 2. This interaction is dose-dependent and clinically significant. Conversely, sildenafil increases bosentan concentrations, with more than twice the expected bosentan levels observed in 53.8% of patients 3.

Preferred Alternative Combinations

Based on 2015 ESC/ERS guidelines 7 and 2019 CHEST guidelines 5:

For WHO Functional Class II-III Patients:

• Ambrisentan + tadalafil (Class I-B recommendation) 7
  • This combination showed a 50% reduction in clinical failure events in the AMBITION trial
  • No significant pharmacokinetic interaction between these agents 3

For WHO Functional Class III-IV Patients:

• Bosentan + intravenous epoprostenol (Class IIa-C) 7
• Triple therapy: Bosentan + sildenafil + intravenous epoprostenol (Class IIa-C) 7
  • This is the only scenario where bosentan-sildenafil combination has guideline support, and only when combined with parenteral prostacyclin

Other ERA + PDE-5i Combinations:

• Macitentan + sildenafil or tadalafil - maintains targeted PDE-5i concentrations without significant interaction 3
• Ambrisentan + sildenafil - shows minimal pharmacokinetic interaction 3

If Patients Are Already on Bosentan + Sildenafil

Transition to alternative therapy is safe and maintains clinical stability 8. In a retrospective study of 16 patients:

• 93.8% tolerated the transition successfully
• 81.8% had stable or improved 6MWD
• All patients maintained stable or improved WHO functional class
• Most common transition: bosentan to macitentan (50% of cases)

Transition Strategy:

1. Switch bosentan to macitentan or ambrisentan while continuing sildenafil
2. Monitor for clinical stability at 1-3 month intervals
3. Assess 6MWD, WHO functional class, and NT-proBNP levels
4. Expect sildenafil concentrations to increase significantly after stopping bosentan 3

Common Pitfalls to Avoid

• Do not assume the combination works simply because both drugs individually improve PAH - the drug interaction undermines efficacy
• Do not use this combination for initial therapy - upfront ambrisentan-tadalafil is superior
• Do not continue this combination without reassessing - transition to non-interacting combinations is safe and evidence-based
• Do not ignore the FDA limitation of use statement - this represents regulatory recognition of inadequate evidence

Clinical Bottom Line

Choose ambrisentan + tadalafil for initial dual oral therapy in WHO FC II-III PAH patients. If patients are already on bosentan + sildenafil, transition to macitentan + sildenafil or ambrisentan + tadalafil to eliminate the pharmacokinetic interaction while maintaining clinical stability. Reserve bosentan + sildenafil only for patients who are also receiving parenteral prostacyclin therapy, where guideline support exists 7.